- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06371508
Breast Cancer and Breast Self-examination Education
The Effect of Breast Cancer and Breast Self-examination Education Given to Women on Breast Cancer Fear and Breast Examination Skills
According to a news published by the World Health Organization (WHO); More than 2.3 million cases of breast cancer occur each year, making it the most common cancer among adults. In 95% of all countries, breast cancer is the first or second cause of female cancer death. In 2020, 2.3 million women worldwide were diagnosed with breast cancer and 685,000 deaths occurred. In Turkey, breast cancer ranks first among the most common cancer types in women, and the number of breast cancer cases in women in 2020 was recorded as 74 638. As a result of this situation, WHO (2023) published the Global Breast Cancer Initiative Framework to save 2.5 million lives from breast cancer by 2040. This published framework includes health promotion for early detection, timely diagnosis and comprehensive management of breast cancer.
One of the most effective ways to reduce breast cancer mortality and morbidity rate is early diagnosis. It is important to determine early diagnosis and signs and symptoms of cancer before they appear. Early diagnosis of breast cancer is possible with breast self-examination (BSE), clinical breast examination and mammography. Breast self-examination is an important examination method in terms of detecting changes in breast tissue and preventing subsequent complications. It is also an easy-to-apply, cheap and non-invasive method. In Turkey, it is recommended that women regularly perform breast self-examination every month after the age of 20, women between the ages of 20 and 40 should have a clinical breast examination every two years, and women between the ages of 40 and 69 should have a clinical breast examination every year and have a mammogram every two years.
There are studies showing that fear of breast cancer has a positive and negative impact on early diagnosis behaviors. Champion et al. (2004) stated that women with moderate breast cancer fear had a high rate of early detection behavior, whereas low and high fear levels had a negative effect on behavior. In the study conducted by Yavan et al. (2010) on 188 women, 2% of the women. They found that 3 of them had regular BSE and 78.7% of them had never had a mammography. In addition, 85% of the women included in the study stated that they had a fear of breast cancer due to a family history of breast cancer, being diagnosed with breast cancer, and the presence of risk factors. Study results show that fear of breast cancer affects screening results. Therefore, aim in the study is; To determine the effect of breast cancer and BSE training given to women on breast cancer fear and BSE skills.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Yalova, Turkey
- Kocadere Sağlık Evi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to read and write,
- Having no history of breast cancer,
- No communication barriers,
- Not pregnant or lactating,
- Those who are willing and agree to participate in the research.
Exclusion Criteria:
- Having a mental illness,
- Those who wish to withdraw from any part of the research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental group
Women in the experimental group of the research will be given training content prepared by the researcher.
The training presentation content will include information about breast cancer, breast cancer screening programs and breast self-examination.
|
Training for the intervention group will be provided with a 40-45 minute training organized by one of the researchers.
|
|
No Intervention: Control group
Women in the control group will not be given any training and only their current information will be determined.
Additionally, their awareness on this issue will be raised as they participate in the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Champion Breast Cancer Fear Scale Change
Time Frame: pre-intervention, 1 month after intervention
|
Breast Cancer Fear Scale; Champion et al.
The scale developed by (2004) is an 8-item, one-dimensional, five-point Likert type measurement tool.
The measurement tool was adapted to Turkish culture by Seçginli (2012).
The items in the scale are scored by the participants as "strongly disagree" 1 point, "disagree" 2 points, "undecided" 3 points, "agree" 4 points, "completely agree" 5 points.
The lowest score from the scale is 8 and the highest score is 40.
As the scores from the scale increase, the level of breast cancer fear increases.
8-15 points from the scale indicate "low level of fear", 16-23 points indicate "medium level fear", and 24-40 points indicate "high level fear".
|
pre-intervention, 1 month after intervention
|
|
Breast Self Examination Checklist Success Score
Time Frame: pre-intervention, 1 month after intervention
|
Breast self-examination proficiency rating instrument-BSEPRI was developed by Robin Wood in 1994.
In the study, the form will be used to evaluate women's ability to perform breast self-examination according to appropriate stages and their ability to detect breast masses.
There are 10 statements in the form that include the stages of performing BSE. 10 points are given for each stage of the examination that is completed correctly, and 0 points are given for any stage that is incorrectly performed or not performed.
Accordingly, a minimum of 0 and a maximum of 100 points are taken from the form.
A BSE score of 90 or above indicates that the BSE was performed correctly, and a score of 80 or below indicates that the BSE was not performed correctly.
|
pre-intervention, 1 month after intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yasemin Hamlacı Başkaya, Phd., Sakarya University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14042024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Education based on breast cancer and breast examination
-
Kırklareli UniversityOrdu University Scientific Research Projects Coordination DepartmentCompletedHealth Education | Women's HealthTurkey
-
Istanbul University - CerrahpasaCompleted
-
Inonu UniversityNot yet recruitingMotivation | Menopausal Women | Breast Cancer Females | Screening Strategy | Education NursingTurkey
-
Federal University of MaranhaoActive, not recruitingBreast Cancer | Breast - Female | Breast Cancer FemalesBrazil
-
Stanford UniversityUniversity of California, BerkeleyCompletedDepression | Breast Cancer | Stress Disorders, Post-traumaticUnited States
-
Istanbul Aydın UniversityActive, not recruiting
-
Yunnan Cancer HospitalNot yet recruiting
-
University of PennsylvaniaCompleted